D. E. Shaw & Co. Becomes 9.5% Owner, Backs Dilutive Restructuring Plan
GOSS sits 22% above its 52-week low of $0.14 on elevated volume (2.0× avg).
Summary
D. E. Shaw & Co. has become a 9.5% beneficial owner of Gossamer Bio by converting $30.29 million in existing debt to equity as part of the company's distressed debt exchange, agreeing to support critical dilutive measures for the company's survival.
Key Events · Ownership and Investor Activity · GOSS
-
D. E. Shaw & Co. Becomes 9.5% Owner
D. E. Shaw & Co. and its affiliated entities now beneficially own 46,485,295 Common Shares, representing 9.5% of Gossamer Bio's outstanding common stock.
-
Debt-to-Equity Conversion Completed
This ownership stake was acquired on June 4, 2026, as part of the early settlement of Gossamer Bio's distressed debt exchange. D. E. Shaw entities converted $30.29 million of existing convertible notes into new shares, new convertible notes, and purchase warrants.
-
Supports Critical Restructuring Proposals
D. E. Shaw has entered into a voting agreement to support shareholder proposals essential for the company's survival, including a massive increase in authorized shares (from 700M to 4B) and a reverse stock split (1-for-10 to 1-for-150).
-
Recent Share Dispositions
Between June 8-11, 2026, D. E. Shaw entities sold approximately 1.9 million shares for a total value of about $300,000, representing a minor adjustment to their overall position.
Analysis · GOSS · Life Sciences
This filing confirms that D. E. Shaw & Co. has become a significant 9.5% beneficial owner of Gossamer Bio. This ownership resulted from converting $30.29 million of existing convertible notes into new equity, new debt, and warrants as part of the company's distressed debt exchange. This is a critical step in Gossamer Bio's ongoing restructuring efforts to avoid bankruptcy and address Nasdaq compliance issues. D. E. Shaw's agreement to vote in favor of highly dilutive measures, including a substantial increase in authorized shares and a reverse stock split, signals institutional support for the company's survival plan, despite the significant dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOSS was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.14 to $3.87. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.